KVP SafePath Partners with Bioguard to Boost Veterinary Diagnostics

KVP SafePath, a subsidiary of KVP International, has entered into a strategic agreement with Bioguard Corporation, located in New Taipei City, Taiwan. The partnership aims to accelerate the development and regulatory approval of veterinary diagnostic assays for the North American market. By utilizing Bioguard's vast library of reagents and intellectual property, KVP SafePath plans to enhance its diagnostic portfolio and reduce development time.

The agreement includes the pursuit of USDA licensing for Canine and Feline 4DX and 3DX testing panels, addressing a market estimated at over $500 million annually in North America. This collaboration builds on the existing relationship between the two companies and grants Bioguard access to the North American market through KVP SafePath's distribution capabilities.

Ken Bowman, CEO of KVP International, highlighted the agreement's role in accelerating market introduction of high-quality assays. Edward Lai, President of Bioguard, acknowledged the move as a significant step towards expanding presence in the largest veterinary diagnostics market globally.